Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zeneca Zomig (311C) NDA filing for migraine expected later this year.

Executive Summary

ZENECA ZOMIG (311C) FOR MIGRAINE NDA FILING LATER THIS YEAR is anticipated after the company completes analysis of Phase III trial data, Zeneca CEO David Barnes stated at the Bear Stearns health care conference Sept. 11 in New York City. "Phase III trials are complete," he noted. Zomig was acquired from Glaxo Wellcome as a result of a Federal Trade Commission- ordered divestiture: Burroughs Wellcome developed 311C, while Glaxo markets Imitrex ("The Pink Sheet" March 20, 1995, p. 11). FTC cleared the acquisition by Zeneca earlier in September.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel